Alpha-9 Oncology Announces Presentation of Data for its GRPR-Targeting Imaging Compound 68Ga-A9-6217 at the European Association of Nuclear Medicine (EANM) 2026 Annual Congress

BOSTON, Mass. and VANCOUVER, British Columbia, October 8th, 2026 – Alpha-9 Oncology Inc. (“Alpha-9”), a clinical-stage radiotherapeutic company developing targeted, next-generation treatments to meaningfully improve the lives of those living with cancer, today announced an upcoming oral presentation supporting the use of 68Ga-A9-6217 PET/CT imaging in patients with gastrin-releasing peptide receptor (“GRPR”) expressing tumors at […] The post Alpha-9 Oncology Announces Presentation of Data for its GRPR-Targeting Imaging Compound 68Ga-A9-6217 at the European Association of Nuclear Medicine (EANM